Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma

Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma

Abstract Chemo-immunotherapy has improved survival in B-cell lymphoma patients, but refractory/relapsed diseases still represent a major challenge, urging for development of new therapeutics. Karonudib (TH1579) was developed to inhibit MTH1, an enzyme preventing oxidized dNTP-incorporation in DNA. M...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Morten P. Oksvold, Ulrika Warpman Berglund, Helge Gad, Baoyan Bai, Trond Stokke, Idun Dale Rein, Therese Pham, Kumar Sanjiv, Geir Frode Øy, Jens Henrik Norum, Erlend B. Smeland, June H. Myklebust, Thomas Helleday, Thea Kristin Våtsveen
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/2bf70b7f4423442fb0d96f1650f44291
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/2bf70b7f4423442fb0d96f1650f44291

Ejemplares similares